Final Technical Report - A Novel Radium-Selective Separation Technique to Improve the Production of ²²⁵Ac for Cancer Immunotherapy

Technical Report · Thu May 11 00:00:00 EDT 2023

OSTI ID:1973138

Drera, Saleem

²²⁵Ac is valuable isotope for radioimmunotherapy treatment of cancers by means of targeted alpha therapy (TAT). However, the production capacity for it is currently insufficient to support the clinical- and commercial-scale demand for TAT drugs. This proposal describes a process for facilitating production of ²²⁵Ac by providing source material in the form of the radium isotopes (primarily ²²⁸Ra) that could become a key precursor in the pathway for efficient production of ²²⁵Ac. RadTran has developed a highly selective, high-yield, simple, scalable, and environmentally conscious process for collecting radium. The separation technique is a variant of molecular recognition technology occurring in a nonconventional chromatography setting. This proposal describes how this technology will be applied to collect ²²⁸Ra from natural thorium and thereby provide material for neutron irradiation-based production of ²²⁹Th (the precursor to ²²⁵Ac). This process can be expanded to ²²⁶Ra production for ²²⁵Ac production and other isotope needs.

• Research Organization: RadTran LLC
• Sponsoring Organization: USDOE Office of Science (SC), Nuclear Physics (NP)
• DOE Contract Number: SC0020568
• OSTI ID: 1973138
• Type / Phase: STTR (Phase I)
• Report Number(s): DOE STTR FY 2020
• Country of Publication: United States
• Language: English